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Abstract
Background: Molecular genotyping is performed in anti-malarial trials to determine whether recurrent
parasitaemia after therapy represents a recrudescence (treatment failure) or new infection. The use of capillary
instead of agarose gel electrophoresis for genotyping offers technical advantages, but it is unclear whether
capillary electrophoresis will result in improved classification of anti-malarial treatment outcomes.
Methods: Samples were genotyped using both gel and capillary electrophoresis from randomized trials of
artemether-lumefantrine (AL) vs. dihydroartemisinin-piperaquine (DP) performed in two areas of Uganda: Kanungu,
where transmission is moderate, and Apac, where transmission is very high. Both gel and capillary methods
evaluated polymorphic regions of the merozoite surface protein 1 and 2 and glutamine rich protein genes.
Results: Capillary electrophoresis detected more alleles and provided higher discriminatory power than agarose gel
electrophoresis at both study sites. There was only moderate agreement between classification of outcomes with
the two methods in Kanungu (kappa = 0.66) and poor agreement in Apac (kappa = 0.24). Overall efficacy results
were similar when using gel vs. capillary methods in Kanungu (42-day risk of treatment failure for AL: 6.9% vs. 5.5%,
p = 0.4; DP 2.4% vs. 2.9%, p = 0.5). However, the measured risk of recrudescence was significantly higher when
using gel vs. capillary electrophoresis in Apac (risk of treatment failure for AL: 17.0% vs. 10.7%, p = 0.02; DP: 8.5%
vs. 3.4%, p = 0.03). Risk differences between AL and DP were not significantly different whether gel or capillary
methods were used.
Conclusions: Genotyping with gel electrophoresis overestimates the risk of recrudescence in anti-malarial trials
performed in areas of high transmission intensity. Capillary electrophoresis provides more accurate outcomes for
such trials and should be performed when possible. In areas of moderate transmission, gel electrophoresis appears
adequate to estimate comparative risks of treatment failure.
Background
When anti-malarial drug efficacy trials are performed in
malaria endemic areas, molecular genotyping is required
to determine whether recurrent parasitaemia after ther-
apy represents a recrudescence (treatment failure) or
new infection [1]. Most commonly, genotyping methods
take advantage of variation in highly polymorphic genes
of Plasmodium falciparum, including merozoite surface
proteins 1 and 2(msp1 and msp2)a n dg l u t a m i n e - r i c h
protein (glurp) [2]. To discriminate P. falciparum
strains, the sizes of amplified products of these genes
are compared, routinely based on migration patterns
with agarose-gel electrophoresis because of ease of use
and low cost. However, gel electrophoresis may not pro-
vide adequate discrimination of alleles, especially in high
transmission settings, where high multiplicity of infec-
tion (MOI) can lead to a large number of genotyping
misclassifications due either to missed detection of
alleles or to alleles matching by chance [3,4]. When the
probability that alleles will match by chance is high,
genotyping-adjusted estimates of the risk of treatment
failure may be grossly overestimated [3,5]. Obtaining
accurate estimates of the risk of treatment failure is
important for guiding policy, as decisions regarding
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estimates.
In response to limitations in standard genotyping
methods, the World Health Organization (WHO)
recently recommended genotyping with capillary elec-
trophoresis, where possible, to increase test sensitivity
and discriminatory power [6]. Capillary electrophoresis
was recommended due to technical advantages over
agarose gel electrophoresis, most importantly the ability
to measure the size of PCR products with very high
resolution. In fact, a recent study found that capillary
electrophoresis detected more msp1 and msp2 alleles
with more precise sizing compared to gel electrophor-
esis [7]. However, in an anti-malarial treatment trial,
this same study demonstrat e dt h a tg e n o t y p i n gu s i n g
msp1 and msp2 with either gel or capillary electrophor-
esis provided identical outcome classifications [7].
Capillary electrophoresis requires expensive equipment
and is not as readily available as gel electrophoresis. At
present, it remains unclear whether capillary electro-
phoresis will, in practice, result in improved classifica-
tion of anti-malarial treatment outcomes compared to
gel electrophoresis and thus whether the added expense
of this methodology is warranted. To critically assess gel
and capillary electrophoresis-based genotyping, the two
methods were directly compared with analysis of msp2,
glurp, and msp1 alleles in clinical samples. Samples were
used from two randomized trials comparing the anti-
malarial efficacy of artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DP) at sites with very
different malaria transmission intensities.
Methods
Study sites and trial design
Clinical samples were utilized from trials conducted at
two sites with markedly different transmission intensi-
ties, Kihihi Health Centre in Kanungu District in wes-
tern Uganda and Aduku Health Centre in Apac District
in central Uganda. In Kanungu, malaria is mesoendemic,
with an entomological inoculation rate (EIR) estimated
at seven infectious bites per person per year [8]. In con-
trast, in Apac, malaria is holoendemic, with an EIR esti-
mated at 1,564 infectious bites per person per year [8].
The details of the clinical trials have been published
elsewhere [5,9]. In both trials, children aged 6 months
to 10 years with uncomplicated falciparum malaria were
randomized to receive either AL or DP and followed for
42 days. Treatment outcomes were assessed according
to WHO guidelines [10]. All subjects with recurrent
parasitaemia detected between 7 and 42 days after the
initiation of therapy had samples genotyped from the
day of treatment (Day 0) and day of identification of
recurrent parasitaemia (day of failure or Day F). Geno-
typing was performed in a stepwise fashion using msp2,
glurp,a n dt h e nmsp1 according to WHO guidelines [6],
with analysis by capillary and gel electrophoresis in par-
allel. As discussed in these guidelines, loci with highest
diversity should be used first. For each locus, if genotyp-
ing assigned an outcome as a new infection (no shared
alleles between days of initial and recurrent parasitae-
mia), no further loci were studied; if genotyping
assigned an outcome as a potential recrudescence (at
least one shared allele), additional loci were assessed, in
the order msp2,t h e nglurp,t h e nmsp1. Sample pairs
which shared at least one allele at every locus success-
fully genotyped were defined as a recrudescence. Those
samples that failed genotyping with msp2 underwent
PCR-based speciation to distinguish between P. falci-
parum and other plasmodial species. Samples containing
only non-falciparum DNA were not genotyped further.
If a sample failed genotyping with all three markers, it
was categorized as having failed molecular genotyping.
Genotyping using agarose gel electrophoresis
Amplification of the polymorphic surface antigens msp2,
glurp,a n dmsp1 was performed according to standard
WHO protocols [6]. In brief, DNA was extracted from
stored blood spots on filter paper into 130 μlo fw a t e r
using a standard Chelex technique [11] and 2 μl of tem-
plate DNA was amplified using nested PCR. PCR was
performed in a Bio-Rad C-1000 thermal cycler (Bio-Rad
Laboratories, Inc, Hercules, CA USA). Primers corre-
sponding to allelic families for msp2 (FC27 and IC3D7)
and msp1 (K1, MAD20, and RO33) and a polymorphic
region of glurp were used as previously described
[12,13]. The resulting PCR products were separated on
a 2.5% agarose gel (UltraPure Agarose: Invitrogen, Carls-
bad, CA) stained with ethidium bromide. A technician
blinded to the identity of the samples estimated the size
of PCR products using GelCompar II software (Applied
Maths, Sint-Martens-Latem, Belgium). Alleles in paired
samples were considered a match for msp2 and msp1 if
within 10 base pairs and for glurp if within 20 base
pairs.
Genotyping using capillary electrophoresis
For capillary electrophoresis, reaction and cycling condi-
tions were optimized based on previously published pro-
tocols before conditions were chosen (primer sequences,
cycling and reaction conditions in Additional File 1,
Table S1). All nested reactions had forward primers
labelled with fluorophores at the 5’ end and reverse pri-
mers tagged with a 5’ GTGTCTT “tail” to promote
addition of an extra adenosine base for more uniform
PCR product sizes [14]. All fluorescent primers except
for the K1 family-specific primer for msp1 used non-
proprietary HEX or 6-FAM labels to minimize cost.
After amplification, the PCR products were prepared
for analysis by mixing 2 μl of 1:10 diluted sample with
10 μl Hi-Di formamide and 0.2 μl of the appropriate
Gupta et al. Malaria Journal 2010, 9:19
http://www.malariajournal.com/content/9/1/19
Page 2 of 8size standard (Genescan 500HD ROX (Applied Biosys-
tems) for msp1 and msp2; Genescan 1000HD ROX
(Applied Biosystems) for glurp. Samples were then dena-
tured at 95°C for 5 minutes and run on an Applied Bio-
systems 3730xl DNA Analyzer. Alleles were sized with
GeneMapper 4.0 software (Applied Biosystems). Alleles
in paired samples were considered a match for msp2
and msp1 if within 1 base. Based on our experience
showing less accurate sizing for larger fragments, alleles
for glurp were considered a match if within 1 base for
alleles <880 bases, 1.5 bases for alleles between 880 and
930, 2 bases for alleles between 930 and 980, 2.5 bases
for alleles between 980 and 1030, and 3 bases for alleles
between 1030 and 1100.
Statistical analysis
Statistical analysis was performed using Stata SE version
10 (StataCorp., College Station, Texas) and R version
2.9.0 (R Foundation for Statistical Computing, Vienna,
Austria). For each locus, the empiric distribution of
allele sizes detected on Day 0 was used to estimate the
probability that two randomly selected alleles will match
by chance without arbitrary binning of alleles. For every
Day 0 allele detected, the proportion of other detected
alleles that met the appropriate match criteria (e.g.
within 10 base pairs for MSP2 gel and 1 base for MSP2
capillary electrophoresis) was calculated and used to
estimate the probability that the particular Day 0 allele
would match another by chance. For example, if 1,000
MSP2 gel alleles were detected in 500 samples, and
allele “A” falls within 10 base pairs in size of 100 of the
other alleles, the probability of that particular allele
matching another by chance is 100/1,000 or 0.1. The
mean of these proportions over all Day 0 alleles was
then used to estimate the overall probability of a match
occurring by chance between two randomly selected
alleles. Of note, two alleles within an allelic family may
match based on size but have different sequences; from
a misclassification standpoint it does not matter whether
two different parasites share a matching allele which dif-
fers based on sequence or is identical in sequence.
The probability of a match (Pmatch) occurring between
the Day 0 and Day F samples, which may both contain
multiple alleles, was calculated by taking into account
the actual alleles present in the Day 0 sample as well as
the number of alleles present in the Day F sample (n).
This probability has previously been calculated after first
assigning each allele to a bin based on size [3]. However,
arbitrary binning of alleles does not accurately reflect
the probability of calling alleles a match in practice, e.g.
alleles of size 299 and 300 may fall into different bins
but would be called a match in practice. Therefore, a
slightly different method was used as follows, which
gives similar results but is less biased, less computation-
ally intensive, and easier to implement. For each sample
pair, 10,000 possible Day F samples were simulated by
randomly selecting combinations of n alleles from the
empiric distribution of Day 0 alleles. The proportion of
t h e s ec o m b i n a t i o n st h a tm e tt h ec r i t e r i af o ram a t c h
with the actual Day 0 sample (at least one allele match-
ing) was then calculated and used to estimate Pmatch for
that sample pair.
A bootstrap with 10,000 repetitions was used to test
the hypothesis that the probability of two alleles match-
ing by chance was the same between gel and capillary
electrophoresis. Given that there were i subjects, in each
bootstrap repetition all the alleles from i Day 0 subjects
from both gel and capillary electrophoresis were
sampled with replacement. The probability of two alleles
matching by chance for both gel and capillary electro-
phoresis was then calculated from the bootstrap sample
as described above, and the difference between these
two probabilities was calculated. The Wilcoxon Rank
Sum test was used for comparisons of other characteris-
tics between gel and capillary electrophoresis. A kappa
statistic was used to test inter-rater agreement between
gel and capillary electrophoresis results. The 42-day risk
of treatment failure was defined as recurrent malaria
due to recrudescent parasites as determined by genotyp-
ing. Risk of failure was estimated using the Kaplan-
Meier product limit formula. Data were censored for
subjects who did not complete 42 days of follow-up and
for new infections. A bootstrap with 1,000 repetitions
was used to test the hypothesis that the 42-day risk of
failure was different between groups.
Results
Samples genotyped
To directly compare the results of gel versus capillary
electrophoresis, the samples from two drug efficacy
trials were independently genotyped with each method,
using the stepwise algorithm of assessing msp2, glurp,
then msp1 recommended by the WHO [6]. In Kanungu,
a region of moderate transmission intensity, 212 chil-
dren were randomized to treatment with DP, of whom
26 (12%) required genotyping, and 196 were treated
with AL, of whom 64 (33%) required genotyping (Figure
1). In Apac, a region of very high transmission intensity,
211 children were randomized to treatment with DP, of
whom 92 (44%) required genotyping, and 210 were trea-
ted with AL, of whom 119 (57%) required genotyping.
Discriminatory ability of gel and capillary electrophoresis
Based on the same criteria used to distinguish alleles in
sample pairs, two msp2 alleles picked at random were 2-
3 times more likely to match using gel versus capillary
electrophoresis due to the greater ability of capillary
electrophoresis to discriminate alleles (Table 1). The
probability of two msp2 alleles matching was very simi-
lar between the sites, indicating a similar degree of
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Figure 2). Similar relationships were seen for glurp and
msp1 with glurp alleles five times more likely and msp1
alleles twice more likely to match by chance with gel
compared to capillary electrophoresis at both sites.
However, a direct comparison between methods can
only be made with msp2, since different sample pairs
were genotyped with gel and capillary electrophoresis at
glurp and msp1 in the stepwise algorithm.
The ability to determine whether a pair of samples
represents a recrudescence or new infection is influ-
enced by the MOI (multiplicity of infection), or number
of strains detected in each sample, as the probability of
having at least one allele match by chance between the
two samples (Pmatch) [3] increases as MOI increases. In
addition, the risk of not detecting a minority allele also
increases as MOI increases, raising the probability of a
recrudescence being misclassified as a new infection. At
both sites, significantly more msp2 alleles were detected
using capillary than gel electrophoresis (Table 1).
Despite the higher MOI identified by capillary electro-
phoresis, this technique yielded a significantly lower
Pmatch than gel electrophoresis due to its higher resolu-
tion. Similar results were seen for glurp and msp1,w i t h
capillary electrophoresis showing a higher MOI and
lower Pmatch than gel electrophoresis. These data suggest
that genotyping misclassification of both recrudescences
and new infections may be lower with capillary than gel
electrophoresis.
Comparing the two trial sites, MOI was higher in Apac
than Kanungu (Table 1). As expected, given the similar
genetic diversity at both sites, Pmatch was higher in Apac
for both gel and capillary methods (p < 0.001 for both
comparisons). Thus, misclassification of new infections
as recrudescences is more likely in Apac than Kanungu.
Agreement between gel and capillary electrophoresis
results
When directly comparing the final genotyping results
from gel and capillary electrophoresis algorithms, mod-
erate agreement was observed (kappa = 0.66) in
Kanungu (Table 2). However, only 11 of 19 (58%) sam-
ple pairs classified as a recrudescence by at least one
method were in agreement (Table 2). At this site, dis-
cordant results occurred approximately equally in both
directions (five recrudescences by gel, three recrudes-
cences by capillary). Fewer genotyping failures were
observed when using the capillary protocol (five failures)
compared to gel electrophoresis (eight failures); all five
capillary genotyping failures were also failures by the gel
protocol.
In Apac, gel and capillary results were more discor-
dant (kappa = 0.24), with only 11 of 53 (21%) sample
Figure 1 Genotyping using markers sequentially at both study sites. Subjects with recurrent parasitaemia in Kanungu and Apac had
samples genotyped in a stepwise fashion in the order shown. A new infection was defined as no alleles matching in samples taken on the day
of treatment and the day of recurrent parasitaemia. A subject not classified as a new infection by one marker was then genotyped sequentially
with the next marker. Those not classified as having a new infection after being genotyped by all three markers were classified as having a
recrudescence, as long as genotyping was successful for at least one marker.
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method in agreement. At this site, most of the discor-
dant results were classified as recrudescences by gel and
new infections by capillary electrophoresis (31 of 42 dis-
cordant results, Table 2). To better understand why
such a high degree of discordance was observed in
Apac, the alleles detected using both methods were ana-
lysed in all discordant samples. In 16 of the 31 (52%)
discordant sample pairs classified as recrudescences by
gel electrophoresis, the alleles classified as recrudescent
had analogous alleles detected by the capillary method.
However, these alleles were sufficiently different in size
to be beyond the more stringent match criteria for
capillary electrophoresis and were thus classified as new
infections. In the remaining 15 sample pairs, the alleles
classified as recrudescent by gel electrophoresis did not
have analogous alleles detected by the capillary method.
In all 11 discordant sample pairs classified as
Figure 2 Allele sizes measured by capillary electrophoresis at both study sites. The y axis represents the probability of an allele of the
given size matching another by chance. As described in the methods, this is calculated as the proportion of all allele measurements from all
Day 0 samples that fall within the specified match criteria (within 1 base in size for msp1 and msp2, greater for glurp alleles 880 bases or larger,
see methods for more detail).
Gupta et al. Malaria Journal 2010, 9:19
http://www.malariajournal.com/content/9/1/19
Page 5 of 8recrudescences by capillary electrophoresis, the alleles
classified as recrudescent by this method did not have
analogous alleles detected by the gel method. Thus, dis-
cordance in results due to missed alleles by one method
or generation of artefact in the other occurred similarly
in both directions, while the more stringent match cri-
teria of capillary electrophoresis largely drove the higher
number of discordant results, which were classified as
recrudescences by gel electrophoresis.
Genotyping-adjusted clinical trial results using gel and
capillary electrophoresis
The analysis was completed by evaluating the results of
the anti-malarial trials using both genotyping modalities.
In Kanungu, a few more sample pairs were classified as
new infections early in the algorithm by capillary elec-
trophoresis (Figure 1), but after all three loci were
assessed, the measured 42-day risks of treatment failure
f o rA La n dD Pw e r es i m i l a rw h e t h e ro u t c o m e sw e r e
classified based on genotyping by gel or capillary
electrophoresis (Table 3). In contrast, in Apac, overall
results for gel and capillary electrophoresis remained
markedly different, with twice as many outcomes classi-
fied as recrudescent with the gel electrophoresis metho-
dology. The measured 42-day risks of treatment failure
for both AL and DP were significantly higher when gen-
otyped using gel rather than capillary electrophoresis.
However, the risk differences between AL and DP were
similar with both genotyping methods. Thus, in
Kanungu genotyping with either method led to similar
measures of treatment outcome, while in Apac the two
methods led to significant differences in absolute, but
not comparative, results for the two treatment arms.
Discussion
Direct comparison of gel and capillary electrophoresis
genotyping methods for two anti-malarial trials showed
that capillary electrophoresis was able to detect more
alleles and provide higher discriminatory power than gel
Table 1 Characteristics of genotyping msp2 using agarose gel versus capillary electrophoresis.
Study Location Characteristic Gel
a CE
b P value
c
Kanungu
(n = 90)
Probability two randomly
selected alleles will match by
chance
d
0.066 0.025 <0.001
MOI Day 0
e, mean (SD) 2.73 (1.53) 3.82 (2.58) <0.001
MOI Day F
f, mean (SD) 1.23 (1.14) 2.02 (1.82) <0.001
Pmatch
g, median (IQR) 0.20 (0.11 - 0.36) 0.16 (0.06 - 0.26) 0.001
Apac
(n = 209)
Probability two randomly
selected alleles will match
0.061 0.028 <0.001
MOI Day 0, mean (SD) 3.65 (1.80) 5.06 (3.42) <0.001
MOI Day F, mean (SD) 2.42 (1.59) 3.26 (2.62) <0.001
Pmatch, median (IQR) 0.41 (0.23 - 0.59) 0.27 (0.12 - 0.50) <0.001
a Gel, Agarose gel electrophoresis
b CE, Capillary electrophoresis
c P values testing the hypothesis Gel is different than CE using a bootstrap test for the probability two alleles will match by chance, and the Wilcoxon Rank Sum
test for other characteristics
d Calculated using the empiric distribution of Day 0 alleles and criteria for a match based on the electrophoresis method
e Multiplicity of infection (number of alleles detected) on Day 0 (day of anti-malarial treatment)
f Multiplicity of infection on Day F (day of failure, i.e. recurrent parasitaemia)
g Probability of a genotyping match occurring by chance for each sample, calculated using the actual alleles present on Day 0 and the multiplicity of infection
on Day F (MOI-F). Ten thousand random combinations of MOI-F alleles were chosen for Day F using the empiric frequency distribution, and Pmatch is the
proportion of these combinations that had at least one allele match with the Day 0 alleles.
Table 2 Agreement between gel and capillary electrophoresis results
Study Location Capillary electrophoresis
result
Gel Electrophoresis result
New Infection Recrudescence Genotyping Failure Total:
Kanungu New Infection 52 5 2 59
Recrudescence 3 11 1 15
Genotyping Failure 0055
Total: 55 16 8 79
Apac New Infection 142 31 1 174
Recrudescence 11 11 0 22
Genotyping Failure 0066
Total: 153 42 7 202
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line with published data using laboratory controls, show-
ing that capillary electrophoresis is more sensitive in
detecting minority alleles than gel electrophoresis and
provides more precise sizing, allowing for better discri-
mination of alleles [7]. These advantages led to mea-
sured genotyping-adjusted risks of treatment failure that
were significantly lower with capillary versus gel electro-
phoresis in a trial conducted in a site with high malaria
transmission, but not in a site with moderate malaria
transmission. A larger difference between methods is
expected in a site of higher transmission intensity, since
a higher proportion of subjects will be genotyped due to
a higher rate of new infections and because the MOI
will often be higher, increasing the risk of genotyping
errors. While absolute risks of treatment failure were
significantly different between the two methods at the
high transmission site, comparative results were similar.
Therefore, using capillary rather than gel electrophoresis
is likely to result in obtaining a more accurate risk of
treatment failure from anti-malarial trials performed in
areas of high transmission intensity, but may not affect
measures of differences in efficacy between treatment
arms.
It is important to note that there were a large number
of discordant results between genotyping methods even
in the trial conducted in Kanungu, an area of moderate
malaria transmission where final anti-malarial trial out-
comes were similar (11 of 19 subjects classified as recru-
descent by at least one method were discordant). The
ability to conduct studies looking for associations
between exposures, such as markers of parasite resistance
or host factors, with the risk of treatment failure requires
analysis on the level of the individual subject. Therefore,
studies aiming to estimate such associations are more
sensitive to genotyping errors than aggregate trial results.
It had been previously shown that genotyping misclassifi-
cation of a small number of subjects can results in a large
difference in association studies [15]. While it is not pos-
sible to say with certainty that the outcome classifications
are more accurate with capillary than gel electrophoresis
in the absence of a gold standard, the higher sensitivity of
detection and higher discrimination of capillary electro-
phoresis suggests that capillary results are more likely
correct. Therefore, anti-malarial studies looking for expo-
sures associated with treatment failure may benefit from
genotyping with capillary electrophoresis even if per-
formed in areas of moderate transmission intensity. The
high degree of discordant results also serves to emphasize
that there are limits to genotyping accuracy, regardless of
the method used, especially when performed in high
transmission areas.
Capillary electrophoresis offers practical as well as tech-
nical advantages over gel electrophoresis. Capillary electro-
phoresis offers higher throughput both for electrophoresis
(96 samples run in about 1 hour) and reading of results,
once familiar with the software. Aside from savings in
labour costs, the capillary method also cost us slightly less
for reagents and consumables, since some of the nested
reactions can be multiplexed and all are performed with
lower reaction volumes when analysed via capillary elec-
trophoresis ($233/96 samples for MSP2 gel vs. $204/96
samples for MSP2 capillary). The major disadvantage of
capillary electrophoresis is the need to have an expensive
machine and software available for analysing samples.
Though widely available in research institutions in the
developed world, this capacity is still not locally available
in many malaria endemic areas. In addition, laboratories
familiar with gel electrophoresis would need to invest time
in learning how to analyse electropherograms to distin-
guish true alleles from artefact. While this analysis can be
automated for microsatellite loci, as stated by other
authors [7], discrimination of alleles of polymorphic sur-
face antigens is still best performed manually due to the
inconsistent nature of artifacts. This is an area that could
benefit from additional work.
Conclusions
Capillary electrophoresis has improved sensitivity and
discriminatory power compared to standard agarose gel
Table 3 Results of clinical trials by genotyping modality
Study Location Treatment Arm Genotyping-corrected
42-day Risk of Treatment Failure, % (95% CI)
Risk Difference,
Gel vs. CE, % (p value)
Gel CE
Kanungu AL 6.9 (3.8-12.1) 5.5 (2.9-10.3) 1.4 (0.4)
DP 2.4 (1.0-5.7) 2.9 (1.3-6.3) -0.5 (0.5)
Risk Difference,
AL vs. DP, % (p value)
4.5 (0.07) 2.6 (0.3)
Apac AL 17.0 (11.8-24.0) 10.7 (6.6-17.1) 6.3 (0.02)
DP 8.5 (5.2-13.7) 3.4 (1.5-7.4) 5.1 (0.03)
Risk Difference,
AL vs. DP, % (p value)
8.5 (0.03) 7.3 (0.02)
Risks of treatment failure calculated using the Kaplan-Meier product limit formula; p-values for risk differences calculated from 1,000 bootstrap repetitions.
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ing anti-malarial trials performed in areas of high trans-
mission intensity, particularly if an outcome of interest
is the absolute risk of treatment failure. In addition,
capillary electrophoresis may improve the ability to
detect associations with treatment failure, even when
studies are not performed in high transmission areas. In
resource-limited settings, where capillary electrophoresis
is not available, agarose gel electrophoresis appears ade-
quate for analysis of comparative rates of treatment fail-
ure in moderate transmission settings.
Additional file 1: Details of PCR primers and conditions for capillary
electrophoresis protocols. Table S1, Details of PCR primers and
conditions for capillary electrophoresis protocols.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-2875-9-19-
S1.DOC]
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